Home › Funds › ORBIMED ADVISORS LLC › TRVI

ORBIMED ADVISORS LLC position in TRVI

TREVI THERAPEUTICS INC · Health Care

ORBIMED ADVISORS LLC reported holding 1,430,293 shares of TRVI (TREVI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$26.7M, representing 0.54% of its reported portfolio and ranking #47 among its reported holdings. ORBIMED ADVISORS LLC has disclosed TRVI holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)1.43M sh
Reported value held$26.67M
Portfolio Weight0.54%
First reportedQ1 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's TRVI position evolved

ORBIMED ADVISORS LLC first disclosed a stake in TRVI in Q1 2025 at 1,120,000 shares (US$7.0M). The position peaked in Q4 2025 at 3,190,700 shares, worth US$39.9M. Across 6 filings, ORBIMED ADVISORS LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,430,293 shares valued at US$26.7M — a reduction of -1,024,107 shares quarter over quarter.. Notable position changes include a 195% increase in Q2 2025 (shares rose 67% over the following quarter), a 42% trim in Q2 2026 (shares fell 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 1.12M $7.04M New
Q2 2025 3.31M $18.10M Add
Q3 2025 3.31M $30.27M Hold
Q4 2025 3.19M $39.95M Reduce
Q1 2026 2.45M $29.28M Reduce
Q2 2026 1.43M $26.67M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRVI and 13F data

TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRVI

All TRVI fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held TRVI?

ORBIMED ADVISORS LLC has disclosed TRVI holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is ORBIMED ADVISORS LLC's current position in TRVI?

As of Q2 2026, ORBIMED ADVISORS LLC holds 1.43M shares of TRVI (TREVI THERAPEUTICS INC), valued at $26.67M, representing 0.54% of its reported portfolio and ranking #47.

Has ORBIMED ADVISORS LLC been buying or selling TRVI?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC reduced its position in TRVI. The position peaked in Q4 2025 at 3.19M shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.